Literature DB >> 6153287

Experimental allergic neuritis in the Lewis rat: characterization of the activity of peripheral myelin and its major basic protein,P2.

M Kadlubowski, R A Hughes, N A Gregson.   

Abstract

Experimental allergic neuritis has been produced in the inbred Lewis rat in the absence of experimental allergic encephalomyelitis (EAE) using bovine intradural root myelin. The lack of EAE is probably because P1 is only weakly encephalitogenic in the rat. One of the basic proteins of bovine peripheral myelin, P2, was isolated and demonstrated to be pure by amino acid analysis and SDS PAGE. It was found to have a molecular weight of 15,400 and contained 4 mol 1/2-cystine/mol. This P2 was found to be highly neuritogenic and is probably the sole neuritogenic antigen in this system. The successful demonstration of its neuritogenicity must be due in large part to the use of the inbred Lewis rat and bovine P2, but an explanation could also involve the omission of denaturing organic solvents, the prevention of oxidative denaturation and presumably the fact that any changes which may occur are not sufficient to prevent recognition of the active site by the immune system of the inbred Lewis rat. P2 was neuritogenic down to 5 micrograms/animal. Its activity was enhanced by but not dependent on the presence of Mycobacterium in the adjuvant. This suggested that release of P2 could possibly break tolerance and produce an auto-immune disease such as the Guillain--Barre syndrome.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6153287     DOI: 10.1016/0006-8993(80)90811-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

1.  Comparative study of experimental autoimmune neuritis in SJL mice and Lewis rats.

Authors:  A Rostami
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

2.  T lymphocyte autoimmunity in peripheral nervous system autoimmune disease.

Authors:  C Linington; H Wekerle; R Meyermann
Journal:  Agents Actions       Date:  1986-12

3.  CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy.

Authors:  C Ekerfelt; J Ernerudh; G Solders; M Vrethem
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

4.  Adoptive transfer of experimental allergic neuritis in the immune suppressed host.

Authors:  A F Hahn; T E Feasby; D Lovgren; L Wilkie
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

5.  Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses.

Authors:  J Zhu; X F Bai; G Hedlund; J Björk; M Bakhiet; P H Van Der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  High numbers of autoantigen-reactive mononuclear cells expressing interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) are present in cord blood.

Authors:  M Yu; S Fredrikson; J Link; H Link
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

8.  Degradation of bovine P2 protein by bovine brain cathepsin D.

Authors:  J N Whitaker; J M Seyer
Journal:  Neurochem Res       Date:  1984-10       Impact factor: 3.996

9.  Immune responses in experimental allergic neuritis.

Authors:  R A Hughes; M Kadlubowski; I A Gray; S Leibowitz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-07       Impact factor: 10.154

10.  Molecular mimicry and the autoimmune response to the peripheral nerve myelin P0 glycoprotein.

Authors:  M Adelmann; C Linington
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.